Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recent advances in artificial blood].

R Motoki, A Usuba, H Inoue

    Nihon Geka Gakkai Zasshi
    |September 1, 1985
    PubMed
    Summary

    Fluosol-DA (FDA), a perfluorochemical emulsion, effectively expands plasma volume and transports oxygen, aiding hemorrhagic shock treatment. Further development aims to overcome limitations for broader clinical use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effect of liposome-encapsulated hemoglobin, neo red cells, on hemorrhagic shock.

    Surgery today·1998
    Same author

    Coronary vascular bed perfusion with a polyethylene glycol-modified hemoglobin-encapsulated liposome, neo red cell, in rats.

    Artificial organs·1998
    Same author

    Liposome encapsulated hemoglobin as a resuscitation fluid for hemorrhagic shock.

    Artificial organs·1998
    Same author

    Effect of liposome encapsulated hemoglobin "neo red cells" on severe hemorrhagic shock.

    Artificial cells, blood substitutes, and immobilization biotechnology·1997
    Same author

    [Respiratory failure after surgery for esophageal cancer and hypercoagulability].

    [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai·1995
    Same author

    Effect and safety of liposome-encapsulated hemoglobin neo red cells (NRCs) as a perfusate for total cardiopulmonary bypass.

    Artificial cells, blood substitutes, and immobilization biotechnology·1995

    Area of Science:

    • Biomaterials Science
    • Hematology
    • Emergency Medicine

    Context:

    • Perfluorochemical emulsions offer oxygen-carrying capacity and plasma volume expansion.
    • Fluosol-DA (FDA) has demonstrated efficacy in treating hemorrhagic shock when blood transfusions are unavailable.
    • Potential applications include organ perfusion and extracorporeal circulation.

    Purpose:

    • To evaluate the efficacy and applications of Fluosol-DA (FDA) as a blood substitute.
    • To identify limitations of current perfluorochemical emulsions.
    • To guide future development of improved perfluorochemical-based therapies.

    Summary:

    • Naito et al. developed Fluosol-DA (FDA), a perfluorochemical emulsion for plasma volume expansion and oxygen transport.
    • FDA proved effective in managing hemorrhagic shock, particularly when blood transfusions were not feasible.
    • Studies explored FDA's use in organ perfusion and its protective effects against ischemia.

    Impact:

    • Current FDA limitations include short intravascular persistence, toxicity, and emulsion instability.
    • Advancements in perfluorochemicals and surfactants are expected to enhance practicality and clinical adoption.
    • Improved perfluorochemical emulsions hold promise for wider therapeutic applications in critical care and surgery.

    Related Experiment Videos